Breast Cancer
CE/CME accredited
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
Favourite
Mark as complete
Videos
Learning Objectives & Overview
Claim Credit
Toolkit
Notes
This activity is CE/CME accredited
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim Credit
You may also be interested in...
CONFERENCE HUB
Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
GO TO HUB
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?
LAUNCH ACTIVITY
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO 2019?
LAUNCH ACTIVITY
CONFERENCE HUB
Bernardo Rapoport, ASCO 2019 – Developments in neoadjuvant breast cancer
GO TO HUB
JOURNALS
Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
GO TO ARTICLE
JOURNALS
Metastatic Breast Cancer—Opportunities from Novel Diagnostic Modalities
GO TO ARTICLE
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Claim Credit
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
You may also be interested in...
touchFOCUS
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
This activity is CE/CME accredited
LAUNCH ACTIVITY
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
GO TO HUB
JOURNALS
FOREWORD – ONCOLOGY & HEMATOLOGY (US) – VOLUME 16 ISSUE 1 – SPRING 2020
GO TO ARTICLE
CONFERENCE HUB
Bernardo Rapoport, ESMO 2018 – Prognostic Factors of Complete Pathological Response
GO TO HUB
Copied to clipboard!
accredited arrow-down-editable arrow-down arrow_left arrow-right-blue arrow-right-dark-blue arrow-right-green arrow-right-grey arrow-right-orange arrow-right-white arrow-right-blue arrow-up-orange avatar calendar chevron-down Clicky Media Logo consultant-pathologist-nurse consultant-pathologist cross cross download email exclaimation feedback filter graph-arrow interviews link mdt_icon more_dots nurse-consultant padlock patient-advocate-pathologist patient-consultant patient person pharmacist-nurse play_button play-colour-tmc play-colour Asset 1 podcast printer scenery search share single-doctor social_facebook social_googleplus social_instagram social_linkedin_alt social_linkedin_alt social_pinterest social_youtube shape-star (1) tick-blue tick-orange tick-red tick-white tick time transcript up-arrow webinar
Department Location NEW TMM Corporate Services Icons-07 NEW TMM Corporate Services Icons-08 NEW TMM Corporate Services Icons-09 NEW TMM Corporate Services Icons-10 NEW TMM Corporate Services Icons-11 NEW TMM Corporate Services Icons-12 Salary £ TMM-Corp-Site-Icons-01 TMM-Corp-Site-Icons-02 TMM-Corp-Site-Icons-03 TMM-Corp-Site-Icons-04 TMM-Corp-Site-Icons-05 TMM-Corp-Site-Icons-06 TMM-Corp-Site-Icons-07 TMM-Corp-Site-Icons-08 TMM-Corp-Site-Icons-09 TMM-Corp-Site-Icons-10 TMM-Corp-Site-Icons-11 TMM-Corp-Site-Icons-12 TMM-Corp-Site-Icons-13 TMM-Corp-Site-Icons-14 TMM-Corp-Site-Icons-15 TMM-Corp-Site-Icons-16 TMM-Corp-Site-Icons-17 TMM-Corp-Site-Icons-18 TMM-Corp-Site-Icons-19 TMM-Corp-Site-Icons-20 TMM-Corp-Site-Icons-21 TMM-Corp-Site-Icons-22 TMM-Corp-Site-Icons-23 TMM-Corp-Site-Icons-24 TMM-Corp-Site-Icons-25 TMM-Corp-Site-Icons-26 TMM-Corp-Site-Icons-27 TMM-Corp-Site-Icons-28 TMM-Corp-Site-Icons-29 TMM-Corp-Site-Icons-30 TMM-Corp-Site-Icons-31 TMM-Corp-Site-Icons-32 TMM-Corp-Site-Icons-33 TMM-Corp-Site-Icons-34 TMM-Corp-Site-Icons-35 TMM-Corp-Site-Icons-36 TMM-Corp-Site-Icons-37 TMM-Corp-Site-Icons-38 TMM-Corp-Site-Icons-39 TMM-Corp-Site-Icons-40 TMM-Corp-Site-Icons-41 TMM-Corp-Site-Icons-42 TMM-Corp-Site-Icons-43 TMM-Corp-Site-Icons-44 TMM-Corp-Site-Icons-45 TMM-Corp-Site-Icons-46 TMM-Corp-Site-Icons-47 TMM-Corp-Site-Icons-48 TMM-Corp-Site-Icons-49 TMM-Corp-Site-Icons-50 TMM-Corp-Site-Icons-51 TMM-Corp-Site-Icons-52 TMM-Corp-Site-Icons-53 TMM-Corp-Site-Icons-54 TMM-Corp-Site-Icons-55 TMM-Corp-Site-Icons-56 TMM-Corp-Site-Icons-57 TMM-Corp-Site-Icons-58 TMM-Corp-Site-Icons-59 TMM-Corp-Site-Icons-60 TMM-Corp-Site-Icons-61 TMM-Corp-Site-Icons-62 TMM-Corp-Site-Icons-63 TMM-Corp-Site-Icons-64 TMM-Corp-Site-Icons-65 TMM-Corp-Site-Icons-66 TMM-Corp-Site-Icons-67 TMM-Corp-Site-Icons-68 TMM-Corp-Site-Icons-69 TMM-Corp-Site-Icons-70 TMM-Corp-Site-Icons-71 TMM-Corp-Site-Icons-72